Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Wendys Co — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Wendys Co trades at $6.48 (market cap $1.21B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.4× Wendys Co's market cap, and Wendys Co pays a 4.41% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Wendys Co for 78 Days on average.
| DYN | WEN | |
|---|---|---|
Market Cap | $2.86B | $1.21B |
Volume | 3,341,579 | 3,737,069 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $9.33 |
52-Week Low | $14.60 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $2.18B | $4.94B |
Dividend Yield | — | 4.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Wendy's stock trades at $6.44, up 2.06% today, but remains near multi-year lows amid ongoing operational challenges. The company shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, while maintaining consistent revenue around $2.2B. However, declining net income margins (5.72% in 2025) and a major franchisee bankruptcy highlight significant headwinds. Technical indicators show bearish momentum with the stock trading near key support levels.
While Wendy's valuation appears compelling, the stock faces substantial risks from declining profitability, high debt levels, and competitive pressures. Analyst consensus leans cautious with a $7.58 price target, suggesting limited upside. The recent CEO change and international expansion plans offer potential catalysts, but execution risks remain elevated given the challenging restaurant environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
